MME
TAK icon

Meag Munich Ergo’s Takeda Pharmaceutical TAK Stock Holding History

Meag Munich Ergo’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-56,401
Closed -$993K – 530
2019
Q2 		$993K Sell
56,401
-41,564
-42% -$756K 0.08% 261
2019
Q1 		$2.02M Buy
+97,965
New +$1.97M 0.17% 143

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM

Meag Munich Ergo's TAK Position: Q3 2019 in Review

Meag Munich Ergo sold out of Takeda Pharmaceutical (TAK) in Q3 2019, closing a stake of 56,401 shares — an estimated $993K sold.

Meag Munich Ergo first reported a position in TAK in Q1 2019 and held it in 2 quarters. The position peaked at $2.02M in Q1 2019. 317 funds tracked by Wall St. Rank hold TAK as of Q3 2019.

  • Meag Munich Ergo reported no remaining Takeda Pharmaceutical position as of Q3 2019 after selling out during the quarter.
  • Meag Munich Ergo sold 56,401 Takeda Pharmaceutical shares in Q3 2019, an estimated $993K.
  • Meag Munich Ergo first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 2 quarters.
  • Meag Munich Ergo's Takeda Pharmaceutical position peaked at $2.02M in Q1 2019.
  • 317 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2019.

Based on Meag Munich Ergo's 13F filing for Q3 2019, filed 29 Oct 2019.